Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

J&J, Vanderbilt U. partner in schizophrenia

Executive Summary

In a three-year collaboration, Johnson & Johnson's Janssen Pharmaceutica NV unit will partner with Vanderbilt University to discover and develop new schizophrenia drugs. Vanderbilt will receive an up-front payment and committed research funding totaling $10mm, plus sales royalties, and reportedly could also get up to $100mm more in research milestones.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
    • Pharmacogenetics-Pharmacogenomics
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies